[1]	Aberer W. Hereditary angioedema:an orphan but an original disease[J]. J Allergy Clin Immunol, 2021, 148(4):994-995.DOI:10.1016/j.jaci.2021.07.026. Cited in this article [1]

[2]	Launay D, Bouillet L, Boccon-Gibod I, et al. Hereditary angioedema and its new treatments:an update[J]. Rev Med Interne, 2023, 44(7):344-353.DOI:10.1016/j.revmed.2023.01.020. Cited in this article [1]

[3]	Santacroce R, D’andrea G, Maffione AB, et al. The genetics of hereditary angioedema:a review[J]. J Clin Med, 2021, 10(9):2023.DOI:10.3390/jcm10092023. Cited in this article [3]

[4]	Quincke HI. Über akutes umschriebenes Hautödem[J]. Monatsh Prakt Dermatol, 1882, 1:129-131. Cited in this article [2]

[5]	Osler W. Hereditary angio-neurotic oedema[J]. Am J Med Sci, 1888, 95:362-367. Cited in this article [1]

[6]	Donaldson VH, Evans RR. A biochemical abnormality in hereditary angioneurotic edema:absence of serum inhibitor of C’1-esterase[J]. Am J Med, 1963, 35(1):37-44.DOI:10.1016/0002-9343(63)90162-1. Cited in this article [1]

[7]	Rosen FS, Pensky J, Donaldson V, et al. Hereditary angioneurotic edema:two genetic variants[J]. Science, 1965, 148(3672):957-958.DOI:10.1126/science.148.3672.957. Cited in this article [1]

[8]	Frank MM, Gelfand JA, Atkinson JP. Hereditary angioedema:the clinical syndrome and its management[J]. Ann Intern Med, 1976, 84(5):580-593.DOI:10.7326/0003-4819-84-5-580. Cited in this article [1]

[9]	Rosen FS, Alper CA, Pensky J, et al. Genetically determined heterogeneity of the C1 esterase inhibitor in patients with hereditary angioneurotic edema[J]. J Clin Invest, 1971, 50(10):2143-2149.DOI:10.1172/jci106708. Cited in this article [1]

[10]	Nussberger J, Cugno M, Amstutz C, et al. Plasma bradykinin in angio-oedema[J]. Lancet, 1998, 351(9117):1693-1697.DOI:10.1016/s0140-6736(97)09137-x. Cited in this article [1]

[11]	Binkley KE, Davis A 3rd. Clinical,biochemical,and genetic characterization of a novel estrogen-dependent inherited form of angioedema[J]. J Allergy Clin Immunol, 2000, 106(3):546-550.DOI:10.1067/mai.2000.108106. Cited in this article [1]

[12]	Bork K, Barnstedt SE, Koch P, et al. Hereditary angioedema with normal C1-inhibitor activity in women[J]. Lancet, 2000, 356(9225):213-217.DOI:10.1016/s0140-6736(00)02483-1. Cited in this article [1]

[13]	支玉香, 安利新, 赖荷, 等. 遗传性血管性水肿的诊断和治疗专家共识[J]. 中华临床免疫和变态反应杂志, 2019, 13(1):1-4.DOI:10.3969/j.issn.1673-8705.2019.01.001. Cited in this article [2]

[14]	Proper SP, Lavery WJ, Bernstein JA. Definition and classification of hereditary angioedema[J]. Allergy Asthma Proc, 2020, 41(6):S03-S07.DOI:10.2500/aap.2020.41.200040. Cited in this article [1]

[15]	曹阳, 刘爽, 支玉香. 遗传性血管性水肿发病机制研究进展[J]. 中国医学科学院学报, 2020, 42(5):686-690.DOI:10.3881/j.issn.1000-503X.11407. Cited in this article [1]

[16]	Maurer M, Magerl M, Betschel S, et al. The international WAO/EAACI guideline for the management of hereditary angioedema-the 2021 revision and update[J]. Allergy, 2022, 77(7):1961-1990.DOI:10.1111/all.15214. Cited in this article [1]

[17]	Wilkerson RG, Moellman JJ. Hereditary angioedema[J]. Emerg Med Clin North Am, 2022, 40(1):99-118.DOI:10.1016/j.emc.2021.09.002. Cited in this article [3]

[18]	Aygören-Pürsün E, Magerl M, Maetzel A, et al. Epidemiology of bradykinin-mediated angioedema:a systematic investigation of epidemiological studies[J]. Orphanet J Rare Dis, 2018, 13(1):73.DOI:10.1186/s13023-018-0815-5. Cited in this article [1]

[19]	Busse PJ, Christiansen SC. Hereditary angioedema[J]. N Engl J Med, 2020, 382(12):1136-1148.DOI:10.1056/NEJMra1808012. Cited in this article [1]

[20]	Kaplan AP, Joseph K. Complement,kinins,and hereditary angioedema:mechanisms of plasma instability when C1 inhibitor is absent[J]. Clin Rev Allergy Immunol, 2016, 51(2):207-215.DOI:10.1007/s12016-016-8555-6. Cited in this article [1]

[21]	De Maat S, Joseph K, Maas C, et al. Blood clotting and the pathogenesis of types Ⅰ and Ⅱ hereditary angioedema[J]. Clin Rev Allergy Immunol, 2021, 60(3):348-356.DOI:10.1007/s12016-021-08837-6. Cited in this article [1]

[22]	Steiner UC, Keller M, Schmid P, et al. Mutational spectrum of the SERPING1 gene in Swiss patients with hereditary angioedema[J]. Clin Exp Immunol, 2017, 188(3):430-436.DOI:10.1111/cei.12941. Cited in this article [1]

[23]	Ponard D, Gaboriaud C, Charignon D, et al. SERPING1 mutation update:mutation spectrum and C1 Inhibitor phenotypes[J]. Hum Mutat, 2020, 41(1):38-57.DOI:10.1002/humu.23917. Cited in this article [1]

[24]	Kaplan AP, Joseph K. Pathogenesis of hereditary angioedema:the role of the bradykinin-forming cascade[J]. Immunol Allergy Clin North Am, 2017, 37(3):513-525.DOI:10.1016/j.iac.2017.04.001. Cited in this article [2]

[25]	Busse PJ, Christiansen SC, Riedl MA, et al. US HAEA medical advisory board 2020 guidelines for the management of hereditary angioedema[J]. J Allergy Clin Immunol Pract, 2021, 9(1):132-150.e133.DOI:10.1016/j.jaip.2020.08.046. Cited in this article [1]

[26]	Levi M, Cohn DM, Zeerleder S. Hereditary angioedema:linking complement regulation to the coagulation system[J]. Res Pract Thromb Haemost, 2019, 3(1):38-43.DOI:10.1002/rth2.12175. Cited in this article [1]

[27]	Cicardi M, Zuraw BL. Angioedema due to bradykinin dysregulation[J]. J Allergy Clin Immunol Pract, 2018, 6(4):1132-1141.DOI:10.1016/j.jaip.2018.04.022. Cited in this article [1]

[28]	Lopez Lera A. Pathophysiology and underlying mechanisms in hereditary angioedema[J]. Balkan Med J, 2021, 38(2):82-88.DOI:10.4274/balkanmedj.galenos.2020.2020.10.166. Cited in this article [1]

[29]	Margaglione M, D’apolito M, Santocroce R, et al. Hereditary angioedema:looking for bradykinin production and triggers of vascular permeability[J]. Clin Exp Allergy, 2019, 49(11):1395-1402.DOI:10.1111/cea.13506. Cited in this article [1]

[30]	Bossi F, Fischetti F, Regoli D, et al. Novel pathogenic mechanism and therapeutic approaches to angioedema associated with C1 inhibitor deficiency[J]. J Allergy Clin Immunol, 2009, 124(6):1303-1310.e1304.DOI:10.1016/j.jaci.2009.08.007. Cited in this article [1]

[31]	Longhurst H, Cicardi M, Craig T, et al. Prevention of hereditary angioedema attacks with a subcutaneous C1 inhibitor[J]. N Engl J Med, 2017, 376(12):1131-1140.DOI:10.1056/NEJMoa1613627. Cited in this article [1]

[32]	Zuraw BL, Cicardi M, Longhurst HJ, et al. Phase Ⅱ study results of a replacement therapy for hereditary angioedema with subcutaneous C1-inhibitor concentrate[J]. Allergy, 2015, 70(10):1319-1328.DOI:10.1111/all.12658. Cited in this article [1]

[33]	Zuraw BL, Christiansen SC. HAE pathophysiology and underlying mechanisms[J]. Clin Rev Allergy Immunol, 2016, 51(2):216-229.DOI:10.1007/s12016-016-8561-8. Cited in this article [1]

[34]	Haslund D, Ryo LB, Seidelin Majidi S, et al. Dominant-negative SERPING1 variants cause intracellular retention of C1 inhibitor in hereditary angioedema[J]. J Clin Invest, 2019, 129(1):388-405.DOI:10.1172/JCI98869. Cited in this article [1]

[35]	Conigliaro P, Triggianese P, Ballanti E, et al. Complement,infection,and autoimmunity[J]. Curr Opin Rheumatol, 2019, 31(5):532-541.DOI:10.1097/bor.0000000000000633. Cited in this article [1]

[36]	Cugno M, Zanichelli A, Bellatorre AG, et al. Plasma biomarkers of acute attacks in patients with angioedema due to C1-inhibitor deficiency[J]. Allergy, 2009, 64(2):254-257.DOI:10.1111/j.1398-9995.2008.01859.x. Cited in this article [1]

[37]	Grover SP, Kawano T, Wan J, et al. C1 inhibitor deficiency enhances contact pathway-mediated activation of coagulation and venous thrombosis[J]. Blood, 2023, 141(19):2390-2401.DOI:10.1182/blood.2022018849. Cited in this article [1]

[38]	Gailani D. Hereditary angioedema and thrombosis[J]. Blood, 2023, 141(19):2295-2297.DOI:10.1182/blood.2023019861. Cited in this article [1]

[39]	Bork K, Wulff K, Witzke G, et al. Treatment for hereditary angioedema with normal C1-INH and specific mutations in the F12 gene (HAE-FXII)[J]. Allergy, 2017, 72(2):320-324.DOI:10.1111/all.13076. Cited in this article [2]

[40]	Bork K, Wulff K, Witzke G, et al. Treatment of patients with hereditary angioedema with the c.988A>G (p.Lys330Glu) variant in the plasminogen gene[J]. Orphanet J Rare Dis, 2020, 15(1):52.DOI:10.1186/s13023-020-1334-8. Cited in this article [1]

[41]	Serrano C, Guilarte M, Tella R, et al. Oestrogen-dependent hereditary angio-oedema with normal C1 inhibitor:description of six new cases and review of pathogenic mechanisms and treatment[J]. Allergy, 2008, 63(6):735-741.DOI:10.1111/j.1398-9995.2007.01579.x. Cited in this article [1]

[42]	Miranda AR, Ue AP, Sabbag DV, et al. Hereditary angioedema type Ⅲ (estrogen-dependent) report of three cases and literature review[J]. An Bras Dermatol, 2013, 88(4):578-584.DOI:10.1590/abd1806-4841.20131818. Cited in this article [1]

[43]	Bork K, Machnig T, Wulff K, et al. Clinical features of genetically characterized types of hereditary angioedema with normal C1 inhibitor:a systematic review of qualitative evidence[J]. Orphanet J Rare Dis, 2020, 15(1):289.DOI:10.1186/s13023-020-01570-x. Cited in this article [2]

[44]	Bork K, Wulff K, Hardt J, et al. Characterization of a partial exon 9/intron 9 deletion in the coagulation factor Ⅻ gene (F12) detected in two Turkish families with hereditary angioedema and normal C1 inhibitor[J]. Haemophilia, 2014, 20(5):e372-e375.DOI:10.1111/hae.12519. Cited in this article [1]

[45]	Cichon S, Martin L, Hennies HC, et al. Increased activity of coagulation factor Ⅻ (Hageman factor) causes hereditary angioedema type Ⅲ[J]. Am J Hum Genet, 2006, 79(6):1098-1104.DOI:10.1086/509899. Cited in this article [1]

[46]	Hashimura C, Kiyohara C, Fukushi JI, et al. Clinical and genetic features of hereditary angioedema with and without C1-inhibitor (C1-INH) deficiency in Japan[J]. Allergy, 2021, 76(11):3529-3534.DOI:10.1111/all.15034. Cited in this article [1]

[47]	Miyata T, Horiuchi T. Biochemistry,molecular genetics,and clinical aspects of hereditary angioedema with and without C1 inhibitor deficiency[J]. Allergol Int, 2023, 72(3):375-384.DOI:10.1016/j.alit.2023.04.004. Cited in this article [2]

[48]	Ivanov I, Matafonov A, Sun MF, et al. A mechanism for hereditary angioedema with normal C1 inhibitor:an inhibitory regulatory role for the factor Ⅻ heavy chain[J]. Blood, 2019, 133(10):1152-1163.DOI:10.1182/blood-2018-06-860270. Cited in this article [1]

[49]	Björkqvist J, De Maat S, Lewandrowski U, et al. Defective glycosylation of coagulation factor Ⅻ underlies hereditary angioedema type Ⅲ[J]. J Clin Invest, 2015, 125(8):3132-3146.DOI:10.1172/jci77139. Cited in this article [1]

[50]	De Maat S, Björkqvist J, Suffritti C, et al. Plasmin is a natural trigger for bradykinin production in patients with hereditary angioedema with factor Ⅻ mutations[J]. J Allergy Clin Immunol, 2016, 138(5):1414-1423.e1419.DOI:10.1016/j.jaci.2016.02.021. Cited in this article [1]

[51]	Kaplan AP, Austen KF. A prealbumin activator of prekallikrein.II.Derivation of activators of prekallikrein from active Hageman factor by digestion with plasmin[J]. J Exp Med, 1971, 133(4):696-712.DOI:10.1084/jem.133.4.696. Cited in this article [1]

[52]	Bork K, Wulff K, Steinmüller-Magin L, et al. Hereditary angioedema with a mutation in the plasminogen gene[J]. Allergy, 2018, 73(2):442-450.DOI:10.1111/all.13270. Cited in this article [1]

[53]	Dewald G. A missense mutation in the plasminogen gene,within the plasminogen kringle 3 domain,in hereditary angioedema with normal C1 inhibitor[J]. Biochem Biophys Res Commun, 2018, 498(1):193-198.DOI:10.1016/j.bbrc.2017.12.060. Cited in this article [1]

[54]	Veronez CL, Csuka D, Sheikh FR, et al. The expanding spectrum of mutations in hereditary angioedema[J]. J Allergy Clin Immunol Pract, 2021, 9(6):2229-2234.DOI:10.1016/j.jaip.2021.03.008. Cited in this article [1]

[55]	Law RH, Caradoc-Davies T, Cowieson N, et al. The X-ray crystal structure of full-length human plasminogen[J]. Cell Rep, 2012, 1(3):185-190.DOI:10.1016/j.celrep.2012.02.012. Cited in this article [1]

[56]	Shamanaev A, Dickeson SK, Ivanov I, et al. Mechanisms involved in hereditary angioedema with normal C1-inhibitor activity[J]. Front Physiol, 2023, 14:1146834.DOI:10.3389/fphys.2023.1146834. Cited in this article [3]

[57]	Kaplan AP. Hereditary angioedema:investigational therapies and future research[J]. Allergy Asthma Proc, 2020, 41(1):S51-S54.DOI:10.2500/aap.2020.41.200056. Cited in this article [1]

[58]	Dickeson SK, Kumar S, Sun MF, et al. A mechanism for hereditary angioedema caused by a lysine 311-to-glutamic acid substitution in plasminogen[J]. Blood, 2022, 139(18):2816-2829.DOI:10.1182/blood.2021012945. Cited in this article [2]

[59]	Wang K, Geiger H, Mcmahon A. Tranexamic acid for ACE inhibitor induced angioedema[J]. Am J Emerg Med, 2021, 43:292.e295-292.e297.DOI:10.1016/j.ajem.2020.10.029. Cited in this article [1]

[60]	Bafunno V, Firinu D, D’apolito M, et al. Mutation of the angiopoietin-1 gene (ANGPT1) associates with a new type of hereditary angioedema[J]. J Allergy Clin Immunol, 2018, 141(3):1009-1017.DOI:10.1016/j.jaci.2017.05.020. Cited in this article [2]

[61]	Ariano A, D’apolito M, Bova M, et al. A myoferlin gain-of-function variant associates with a new type of hereditary angioedema[J]. Allergy, 2020, 75(11):2989-2992.DOI:10.1111/all.14454. Cited in this article [2]

[62]	Baffert F, Le T, Thurston G, et al. Angiopoietin-1 decreases plasma leakage by reducing number and size of endothelial gaps in venules[J]. Am J Physiol Heart Circ Physiol, 2006, 290(1):H107-H118.DOI:10.1152/ajpheart.00542.2005. Cited in this article [1]

[63]	D’apolito M, Santacroce R, Colia AL, et al. Angiopoietin-1 haploinsufficiency affects the endothelial barrier and causes hereditary angioedema[J]. Clin Exp Allergy, 2019, 49(5):626-635.DOI:10.1111/cea.13349. Cited in this article [1]

[64]	Zuraw BL. Hereditary angioedema with normal C1 inhibitor:four types and counting[J]. J Allergy Clin Immunol, 2018, 141(3):884-885.DOI:10.1016/j.jaci.2018.01.015. Cited in this article [1]

[65]	Loules G, Parsopoulou F, Zamanakou M, et al. Deciphering the genetics of primary angioedema with normal levels of C1 inhibitor[J]. J Clin Med, 2020, 9(11):3402.DOI:10.3390/jcm9113402. Cited in this article [1]

[66]	Bork K, Wulff K, Rossmann H, et al. Hereditary angioedema cosegregating with a novel kininogen 1 gene mutation changing the N-terminal cleavage site of bradykinin[J]. Allergy, 2019, 74(12):2479-2481.DOI:10.1111/all.13869. Cited in this article [1]

[67]	Bernatchez PN, Acevedo L, Fernandez-Hernando C, et al. Myoferlin regulates vascular endothelial growth factor receptor-2 stability and function[J]. J Biol Chem, 2007, 282(42):30745-30753.DOI:10.1074/jbc.M704798200. Cited in this article [1]

[68]	Bork K, Wulff K, Möhl BS, et al. Novel hereditary angioedema linked with a heparan sulfate 3-O-sulfotransferase 6 gene mutation[J]. J Allergy Clin Immunol, 2021, 148(4):1041-1048.DOI:10.1016/j.jaci.2021.01.011. Cited in this article [1]

[69]	Chopra P, Joshi A, Wu J, et al. The 3-O-sulfation of heparan sulfate modulates protein binding and lyase degradation[J]. Proc Natl Acad Sci U S A, 2021, 118(3):e2012935118.DOI:10.1073/pnas.2012935118. Cited in this article [1]

[70]	Mochizuki H, Futatsumori H, Suzuki E, et al. A quantitative method to detect non-antithrombin-binding 3-O-sulfated units in heparan sulfate[J]. J Biol Chem, 2021, 296:100115.DOI:10.1074/jbc.RA120.015864. Cited in this article [1]